Skip to main content
Top
Published in: Pituitary 3/2008

01-09-2008 | Case Report

Triple jeopardy in the pituitary

Authors: Kian-Peng Goh, Hwei-Yee Lee, Raja C. Rajasoorya

Published in: Pituitary | Issue 3/2008

Login to get access

Abstract

Aggressive pituitary tumors are rare the pathogenesis is not well established. The development of pituitary tumor after apoplexy has also been rarely reported. We describe the sequential development of Cushing’s disease, apoplexy and aggressive pituitary tumor in the same patient. A 31-year old male presented with eutopic ACTH dependent Cushing’s syndrome which failed initial pituitary surgery. He underwent subsequent bilateral adrenalectomy for control of hypercortisolism. An episode of pituitary apoplexy then occurred which was followed by the development of a null-cell pituitary tumor. This second tumor exhibited an aggressive behavior with invasion into the surrounding structures and systemic spread clinically. This case provides important evidence for the hypotheses of the pathogenesis of aggressive pituitary tumors which could have arisen from surviving adenoma cells following apoplexy or as a de novo development of pituitary carcinoma from cells which were not part of the original adenoma. This is the first report of a transformation of Cushing’s disease to an aggressive and invasive null cell tumor after pituitary irradiation, apoplexy and surgery.
Literature
1.
go back to reference Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120:817–820PubMed Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120:817–820PubMed
3.
go back to reference Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812PubMedCrossRef Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812PubMedCrossRef
4.
go back to reference Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16:E7PubMedCrossRef Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16:E7PubMedCrossRef
5.
go back to reference Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647–672PubMedCrossRef Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647–672PubMedCrossRef
6.
go back to reference Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–770PubMedCrossRef Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–770PubMedCrossRef
7.
go back to reference Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T (1992) Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol (Berl) 84:178–183CrossRef Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T (1992) Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol (Berl) 84:178–183CrossRef
8.
go back to reference Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089–3099PubMedCrossRef Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089–3099PubMedCrossRef
9.
go back to reference Rickert CH, Scheithauer BW, Paulus W (2001) Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol (Berl) 102:117–120 Rickert CH, Scheithauer BW, Paulus W (2001) Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol (Berl) 102:117–120
10.
go back to reference Kumar K, Macaulay RJ, Kelly M, Pirlot T (2001) Absent p53 immunohistochemical staining in a pituitary carcinoma. Can J Neurol Sci 28:174–178PubMed Kumar K, Macaulay RJ, Kelly M, Pirlot T (2001) Absent p53 immunohistochemical staining in a pituitary carcinoma. Can J Neurol Sci 28:174–178PubMed
11.
go back to reference Kemink SA, Wesseling P, Pieters GF, Verhofstad AA, Hermus AR, Smals AG (1999) Progression of a Nelson’s adenoma to pituitary carcinoma: a case report and review of the literature. J Endocrinol Invest 22:70–75PubMed Kemink SA, Wesseling P, Pieters GF, Verhofstad AA, Hermus AR, Smals AG (1999) Progression of a Nelson’s adenoma to pituitary carcinoma: a case report and review of the literature. J Endocrinol Invest 22:70–75PubMed
12.
go back to reference Scheithauer BW, Kurtkaya-Yapicier O, Young WF, Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56:1066–1074PubMed Scheithauer BW, Kurtkaya-Yapicier O, Young WF, Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56:1066–1074PubMed
13.
go back to reference Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JM, Doppman JL, Oldfield EH, Weintraub BD (1993) Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 76:529–533PubMedCrossRef Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JM, Doppman JL, Oldfield EH, Weintraub BD (1993) Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 76:529–533PubMedCrossRef
14.
go back to reference Findling JW, Tyrrell JB, Aron DC, Fitzgerald PA, Wilson CB, Forsham PH (1981) Silent pituitary apoplexy: subclinical infarction of an adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab 52:95–97PubMedCrossRef Findling JW, Tyrrell JB, Aron DC, Fitzgerald PA, Wilson CB, Forsham PH (1981) Silent pituitary apoplexy: subclinical infarction of an adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab 52:95–97PubMedCrossRef
15.
go back to reference Moore TJ, Dluhy RG, Williams GH, Cain JP (1976 Nelson’s syndrome: frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med 85:731–734PubMed Moore TJ, Dluhy RG, Williams GH, Cain JP (1976 Nelson’s syndrome: frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med 85:731–734PubMed
16.
go back to reference Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 92:172–179PubMedCrossRef Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 92:172–179PubMedCrossRef
17.
go back to reference Pereira MA, Halpern A, Salgado LR, Mendonça BB, Nery M, Liberman B, Streeten DH, Wajchenberg BL (1998) A study of patients with Nelson’s syndrome. Clin Endocrinol (Oxf) 49:533–539CrossRef Pereira MA, Halpern A, Salgado LR, Mendonça BB, Nery M, Liberman B, Streeten DH, Wajchenberg BL (1998) A study of patients with Nelson’s syndrome. Clin Endocrinol (Oxf) 49:533–539CrossRef
18.
go back to reference Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, Rajan B, Traish D (1992) Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 304:1343–1346PubMed Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, Rajan B, Traish D (1992) Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 304:1343–1346PubMed
19.
go back to reference Gittoes NJ (2005) Pituitary radiotherapy: current controversies. Trends Endocrinol Metab 16:407–413PubMedCrossRef Gittoes NJ (2005) Pituitary radiotherapy: current controversies. Trends Endocrinol Metab 16:407–413PubMedCrossRef
20.
go back to reference Kamiya Y, Jin-No Y, Tomita K, Suzuki T, Ban K, Sugiyama N, Mase M, Sakuma N, Kimura G (2000) Recurrence of Cushing’s disease after long-term remission due to pituitary apoplexy. Endocr J 47:793–797PubMedCrossRef Kamiya Y, Jin-No Y, Tomita K, Suzuki T, Ban K, Sugiyama N, Mase M, Sakuma N, Kimura G (2000) Recurrence of Cushing’s disease after long-term remission due to pituitary apoplexy. Endocr J 47:793–797PubMedCrossRef
21.
go back to reference Werner PL, Shah JH, Kukreja SC, Miller SM, Williams GA (1982) Recurrence of acromegaly after pituitary apoplexy. JAMA 247:2816–2818PubMedCrossRef Werner PL, Shah JH, Kukreja SC, Miller SM, Williams GA (1982) Recurrence of acromegaly after pituitary apoplexy. JAMA 247:2816–2818PubMedCrossRef
22.
go back to reference Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51:181–188CrossRef Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51:181–188CrossRef
23.
go back to reference Verrees M, Arafah BM, Selman WR (2004) Pituitary tumor apoplexy: characteristics, treatment, and outcomes. Neurosurg Focus 16:E6PubMedCrossRef Verrees M, Arafah BM, Selman WR (2004) Pituitary tumor apoplexy: characteristics, treatment, and outcomes. Neurosurg Focus 16:E6PubMedCrossRef
24.
go back to reference Horvath E, Scheithauer BW, Kovacs K, Lloyd RV (2002) Hypothalamus and pituitary. In: Graham DI, Lantos PL (eds) Greenfield’s neuropathology, 7th edn, vol 1. Arnold, London, p 1024 Horvath E, Scheithauer BW, Kovacs K, Lloyd RV (2002) Hypothalamus and pituitary. In: Graham DI, Lantos PL (eds) Greenfield’s neuropathology, 7th edn, vol 1. Arnold, London, p 1024
25.
go back to reference Tan EU, Ho MS, Rajasoorya CR (2000) Metamorphosis of a non-functioning pituitary adenoma to Cushing’s disease. Pituitary 3:117–122PubMedCrossRef Tan EU, Ho MS, Rajasoorya CR (2000) Metamorphosis of a non-functioning pituitary adenoma to Cushing’s disease. Pituitary 3:117–122PubMedCrossRef
Metadata
Title
Triple jeopardy in the pituitary
Authors
Kian-Peng Goh
Hwei-Yee Lee
Raja C. Rajasoorya
Publication date
01-09-2008
Publisher
Springer US
Published in
Pituitary / Issue 3/2008
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-007-0075-1

Other articles of this Issue 3/2008

Pituitary 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine